While standard chemoimmunotherapy is less effective in patients with these mutations, targeted agents such as BTK inhibitors (e.g., ibrutinib) and BCL-2 inhibitors (e.g., venetoclax) have shown better clinical outcomes in SF3B1-mutated CLL [197,198]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.